Nadine Andrieu

List of Publications by Year
in descending order

30 papers	3,174 citations	471061 17 h-index	433756 31 g-index
33 all docs	33 docs citations	33 times ranked	5184 citing authors

#	Article	IF	Citations
1	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA - Journal of the American Medical Association, 2017, 317, 2402.	3.8	1,898
2	Effect of Chest X-Rays on the Risk of Breast Cancer Among BRCA1/2 Mutation Carriers in the International BRCA1/2 Carrier Cohort Study: A Report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaboratorsâ€™ Group. Journal of Clinical Oncology, 2006, 24, 3361-3366.	0.8	188
3	Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ, The, 2012, 345, e5660-e5660.	3.0	186
4	A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genetic Epidemiology, 2005, 29, 1-11.	0.6	136
5	Cancer risk in heterozygotes for ataxia-telangiectasia. International Journal of Cancer, 2001, 93, 288-293.	2.3	124
6	FANCMc.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Human Molecular Genetics, 2015, 24, 5345-5355.	1.4	91
7	Age at Menarche and Menopause and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 740-746.	1.1	63
8	Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing. International Journal of Cancer, 2019, 144, 1962-1974.	2.3	50
9	Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO). Breast Cancer Research and Treatment, 2011, 130, 927-938.	1.1	46
10	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2020, 22, 8.	2.2	41
11	Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers. Breast Cancer Research, 2018, 20, 28.	2.2	35
12	Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. American Journal of Obstetrics and Gynecology, 2021, 225, 51.e1-51.e17.	0.7	34
13	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectrum, 2018, 2, pky023.	1.4	33
14	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 368-378.	1.1	24
15	Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location inBRCA1/2Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 698-707.	1.1	21
16	The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations. JNCI Cancer Spectrum, 2018, 2, pky078.	1.4	21
17	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	5.8	19
18	Mutation analysis of PALB2 gene in French breast cancer families. Breast Cancer Research and Treatment, 2015, 154, 463-471.	1.1	17

#	Article	IF	Citations
19	Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia families. Carcinogenesis, 2017, 38, 994-1003.	1.3	17
20	GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers. Frontiers in Oncology, 2018, 8, 490.	1.3	14
21	GENESIS: a French national resource to study the missing heritability of breast cancer. BMC Cancer, 2016, 16, 13.	1.1	13
22	Ataxia-Telangiectasia genes and breast cancer risk in a French family study. Journal of Dairy Research, 2005, 72, 73-80.	0.7	12
23	Targeted Sequencing of the Mitochondrial Genome of Women at High Risk of Breast Cancer without Detectable Mutations in BRCA1/2. PLoS ONE, 2015, 10, e0136192.	1.1	11
24	First international workshop of the ATM and cancer risk group (4-5 December 2019). Familial Cancer, 2022, 21, 211-227.	0.9	10
25	Mutation screening of MIR146A/B and BRCA1/2 3â€²-UTRs in the GENESIS study. European Journal of Human Genetics, 2016, 24, 1324-1329.	1.4	8
26	Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits. Journal of the National Cancer Institute, 2022, 114, 540-552.	3.0	7
27	Geneâ€•and pathwayâ€‐level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibility. International Journal of Cancer, 2021, 148, 1895-1909.	2.3	5
28	Boosting GWAS using biological networks: A study on susceptibility to familial breast cancer. PLoS Computational Biology, 2021, 17, e1008819.	1.5	4
29	A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers. BMC Medical Research Methodology, 2021, 21, 155.	1.4	3
30	Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation. Breast Cancer Research, 2021, 23, 79.	2.2	3